Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251930 | 0.82 | SYK (0.48) | ABCG2SYKMAP4K4HRH4KMO | |
| SCHEMBL2596769 | 0.80 | ASIC3 (0.65) | MAP4K4CAMK2DASIC3HRH4NUDT1 | |
| SCHEMBL246458 | 0.79 | ABCG2 (0.48) | ABCG2SYKMAP4K4NUDT1KMO | |
| SCHEMBL2302917 | 0.75 | NPC1 (0.46) | ASIC3HCAR2 | |
| SCHEMBL4248549 | 0.72 | ALDH1A1 (0.55) | KMO | |
| SCHEMBL4106824 | 0.72 | ASIC3 (0.50) | MAP4K4CAMK2DASIC3HRH4KMO | |
| SCHEMBL11364757 | 0.71 | SYK (0.60) | SYKMAP4K4HRH4CYP19A1DHFR | |
| SCHEMBL12425137 | 0.70 | TGFBR1 (0.49) | ABCG2SYKMAP4K4PLK1 | |
| SCHEMBL12692408 | 0.70 | ASIC3 (0.53) | ASIC3DHFR | |
| SCHEMBL2328465 | 0.69 | MET (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539336-B1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8815893-B2 | Hetarylaminonaphthyridines | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2539336-A2 | HETARYLAMINONAPHTHYRIDINES | Merck Patent GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101069-A2 | HETARYLAMINONAPHTHYRIDINES | MERCK PATENT GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316166-A1 | HETARYLAMINONAPHTHYRIDINES | ATP5ME, ATP5F1A, ATP5F1D | ABCG2 175/4885SYK 3462/4885MAP4K4 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.